According to a recent LinkedIn post from Levee Medical, Tampa General Hospital and Dr. Trushar Patel have enrolled their first patient in the ARID II IDE pivotal trial. The study is described as evaluating the Voro® Urologic Scaffold and its impact on early and long-term continence outcomes following prostate surgery.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights this milestone as progress in advancing post-prostatectomy care and improving patient outcomes. For investors, successful progression of a pivotal IDE trial could be an important step toward eventual regulatory clearance, potential commercialization of Voro, and validation of Levee Medical’s technology in the urologic surgery market.
If the trial demonstrates meaningful improvements in continence, it may strengthen the company’s competitive position in post-surgical urologic care and support future partnerships with hospitals and urology practices. However, the post does not provide timelines, enrollment targets, or regulatory guidance, leaving uncertainty around development risk, time to market, and eventual revenue impact.